Patents by Inventor David S. Wilson, JR.

David S. Wilson, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20240076343
    Abstract: Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 7, 2024
    Inventors: David S. WILSON, JR., Kim Tran YAP, Paul AYTON, Debasish SEN, Julia ROZENFELD, Sachin Badrinath SURADE, Anthony Gerard DOYLE
  • Anti-CD43 antibody and use thereof for cancer treatment
    Patent number: 11542339
    Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: January 3, 2023
    Assignee: APROGEN INC.
    Inventors: Kwon Pyo Hong, Sangsoon Yoon, Irene Koukoulas, Vincent Batori, Briony Cristiano, David S Wilson, Jr., George Kopsidas
  • Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
    Patent number: 11117975
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 14, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 10981986
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 20, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • ANTI-CD43 ANTIBODY AND USE THEREOF FOR CANCER TREATMENT
    Publication number: 20200392240
    Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
    Type: Application
    Filed: May 11, 2020
    Publication date: December 17, 2020
    Inventors: Kwon Pyo HONG, Sangsoon YOON, Irene KOUKOULAS, Vincent BATORI, Briony CRISTIANO, David S. WILSON, JR., George KOPSIDAS
  • Anti-CD43 antibody and use thereof for cancer treatment
    Patent number: 10676531
    Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 9, 2020
    Assignee: APROGEN KIC INC.
    Inventors: Kwon Pyo Hong, Sangsoon Yoon, Irene Koukoulas, Vincent Batori, Briony Cristiano, David S Wilson, Jr., George Kopsidas
  • ANTI-CD43 ANTIBODY AND USE THEREOF FOR CANCER TREATMENT
    Publication number: 20190016813
    Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
    Type: Application
    Filed: October 12, 2016
    Publication date: January 17, 2019
    Inventors: Kwon Pyo HONG, Sangsoon YOON, Irene KOUKOULAS, Vincent BATORI, Briony CRISTIANO, David S WILSON JR, George KOPSIDAS
  • ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
    Publication number: 20180305460
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Application
    Filed: April 19, 2018
    Publication date: October 25, 2018
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, JR., Sarah L. Pogue, Tetsuya Taura
  • Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
    Patent number: 9963515
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: May 8, 2018
    Assignee: Teva Pharmaceuticals Australia Pty Ltd.
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura
  • FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA
    Publication number: 20170233449
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: March 2, 2017
    Publication date: August 17, 2017
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 9611322
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
    Publication number: 20160068612
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Application
    Filed: October 26, 2015
    Publication date: March 10, 2016
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, JR., Sarah L. Pogue, Tetsuya Taura
  • POLYPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20140248238
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: April 28, 2014
    Publication date: September 4, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, JR., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin